Skip to main content
FOETAL CHROMOSOMAL STUDY BY DNA TEST FROM MOTHER BLOOD IN EARLY PREGNANCY LAUNCHED:PNDT COVERAGE TO MISUSE IT AS SEX DETERMINATION.
FOETAL CHROMOSOMAL STUDY BY DNA TEST FROM MOTHER BLOOD IN EARLY PREGNANCY LAUNCHED:PNDT COVERAGE TO MISUSE IT AS SEX DETERMINATION.
DR.MRS.RANJU NAKIPURIA,SENIOR GYNAECOLOGIST,OBST & INFERTILITY EXPERT
drrnakipuria@gmail.com, 09434143550, +917503303359,07838059592,+919832025033.,
FOLLOW ON FACE BOOK:www.facebook.com/drrnakipuria
FOLLOW ON TWITTER:www.twitter.com/dr.d.r.nakipuria
The sophisticated blood test examines fetal DNA in the maternal bloodstream to determine whether baby is at risk of certain chromosomal disorders like Down syndrome, extra sequences of chromosome 13 (trisomy 13), extra sequences of chromosome 18 (trisomy 18) or a sex chromosome abnormality, such as Turner syndrome. The testing can also be used to determine a baby's sex and rhesus (Rh) blood type.
This is a blood test which can be done as early as six to eight weeks of pregnancy and by examining the mother's blood-FOETAL DNA TEST CAN BE DONE.The test analyzes fetal DNA found in a mother's blood. The presence of Y chromosome confirms the sex of the fetus as male.More sophisticated techniques for sex determination using modern technology of DNA-based diagnosis are developed which use a pregnant mother's blood, or placental cells collected via cervix to detect the presence of Y chromosome in the fetal cells.
This test allows the detection of Y chromosome in the seventh or the eighth week of pregnancy. There is an urgent need to bring these tests under PCPNDT Act. Hence it is important to register all such laboratories which will be carrying out these tests under the heading of genetic laboratories under PCPNDT act."
A Mumbai-based diagnostic firm is going to launch the test kit next month. "We don't want this test to be used as a method of gender selection. The aim is to offer the non-invasive blood test to predict the risk for chromosomal disorder like trisomy," said Anil Thatte of a Mumbai-based diagnostic firm. Trisomy is a chromosomal disorder characterised by an additional chromosome.
"We are going to launch the test kit next month. The test kit will be available with gynaecologists as per their requirements. The blood sample of the pregnant woman drawn through the test kit will be collected and sent by air to a US-based firm where it will be tested for certain chromosomal disorders. We are ready to follow all the regulations and norms under the PCPNDT Act," Thatte said.
the sex-determination methods which were mentioned in the PCPNDT Act have improved substantially over the past decade. With the advent in technology, more invasive techniques such as amniocentesis (the sampling of amniotic fluid during pregnancy) and chorion villus biopsy (sampling of placental tissue to diagnose genetic abnormalities) have taken a back seat as they are associated with higher chances of injury to the developing fetus and even it will replace DUL MARKER OR TRIPLE MARKER TESTS DONE IN PREGNACY PERIOD TO SEE FOETAL ABNORMALITIES .Hence there is need to broaden the scope of the PCPDNT Act. — with Shreya Nakipuria and 2 others.
Comments
Post a Comment